Clinical Trials

Are you an adult with atrial fibrillation? In this study, researchers are comparing a continuous direct oral anticoagulation (DOAC) use versus time-limited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) for persons with atrial fibrillation and a moderate risk of stroke. Participants must be between the ages of 22 and 85 and have a history of atrial fibrillation. The study is taking place at locations in California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Texas, Virginia, Wisconsin, and Washington, D.C.

Did you develop atrial fibrillation after coronary artery bypass graft (CABG) surgery? Did you develop atrial fibrillation after a coronary artery bypass grafting (CABG) surgery? This study is looking at how well oral anticoagulation medicines work to prevent complications, such as blood clots and heart attack, for patients who experience post-operative atrial fibrillation (POAF). This study is in multiple locations around the country.

Do you have heart failure? In this clinical trial, researchers are using images of the heart and blood tests to learn more about Black and Hispanic patients with heart failure. You may be able to participate if you are at least 60 years old; of Black, Hispanic, or Caribbean origin; and have been diagnosed with heart failure. The study is taking place in locations in Connecticut, Massachusetts, and New York.

Have you been diagnosed with peripartum cardiomyopathy and are within 5 months of your due date? This study is evaluating the effectiveness of a medicine called bromocriptine to treat peripartum cardiomyopathy, or weakness of the heart muscle that occurs during or shortly after pregnancy. To participate in this study, you must be at least 18 years old, diagnosed with peripartum cardiomyopathy, and within 5 months of your delivery date. This study takes place in Pittsburgh, Pennsylvania.

The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.

Are you in need of a heart or lung transplant or have you had one in the past 3 months? Have you undergone a lung or heart transplant in the past 3 months or are you a candidate for heart or lung transplant? Some people with advanced heart and lung disease have heart and lung transplants but these new organs are often rejected. When this happens, patients must have repeated biopsies, which are invasive and expensive. Researchers in this clinical study want to see if a blood test can predict organ rejection and take the place of biopsies. To participate, you must be 18 to 80 years old and be a candidate for heart or lung transplant or have had a heart or lung transplant no more than three months ago. The study is taking place in Bethesda, Maryland, at the NIH Clinical Center, as well as in Baltimore, Maryland, and Falls Church, Virginia.